10-Q: Celularity Faces Going Concern Warning Amid Nasdaq Delays

Celularity Inc. reported a substantial decrease in product sales and ongoing operating losses, leading to a going concern warning and Nasdaq non-compliance notices.

Summary

• Celularity Inc. reported a significant decrease in product sales for the first quarter of 2026 compared to the prior year, primarily due to lower sales of Biovance 3L and Rebound products, influenced by uncertainty in Medicare reimbursement for skin substitute grafts.
• Total revenues decreased by 66.3% to $3.8 million for the three months ended March 31, 2026, from $11.4 million in the same period of 2025.
• Operating expenses also decreased by 36.2% to $14.0 million, largely due to reduced cost of product revenues and lower selling, general, and administrative expenses.
• The company reported a net income of $0.9 million for the quarter, a significant improvement from a net loss of $19.8 million in the prior year, largely driven by $12.2 million in proceeds from the sale of New Jersey net operating loss carryforwards and the absence of a large debt extinguishment loss.
• Despite the reported net income, the company has substantial accumulated deficits ($990.6 million) and a working capital deficit ($64.3 million), leading to a going concern warning.
• Celularity received multiple notices from Nasdaq for non-compliance, including failure to file reports on time and maintaining a minimum market value of listed securities below the required threshold.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to significant going concern warnings, Nasdaq non-compliance, and substantial operating losses, despite some recent revenue increases and strategic transactions.

Positives

• Reported net income of $0.9 million for the three months ended March 31, 2026, a significant improvement from a net loss of $19.8 million in the prior year.
• Proceeds of $12.2 million from the sale of New Jersey net operating loss carryforwards contributed positively to the quarter's results.
• Absence of a $5.7 million loss on debt extinguishment, which was recorded in the prior year.
• License, royalty, and other revenues increased by 73.0% to $1.7 million, partly due to the Biocellgraft arrangement.
• The company entered into a significant Asset Purchase and Exclusive License Agreement with NexGel, Inc., potentially worth up to $35 million, which closed in April 2026.
• A new financing round closed on September 24, 2026, providing approximately $11.0 million in gross proceeds.

Negatives

• Product sales decreased by 90.4% to $0.9 million, primarily due to lower sales of Biovance 3L and Rebound products, impacted by Medicare reimbursement uncertainties.
• Total revenues decreased by 66.3% to $3.8 million.
• The company has substantial accumulated deficits of $990.6 million as of March 31, 2026.
• A working capital deficit of $64.3 million was reported as of March 31, 2026.
• The company received multiple notices from Nasdaq for non-compliance, including late filings and low market value, raising concerns about continued listing.
• Significant doubt exists about the company's ability to continue as a going concern within one year.
• The company defaulted on payments related to the Helena Settlement and is currently negotiating to resolve the breach.
• The company is facing potential delisting from Nasdaq, which could severely impair liquidity and market value.

Risks

• Substantial doubt about the company's ability to continue as a going concern within one year due to recurring operating losses, working capital deficits, insufficient cash reserves, and debt maturities.
• Failure to regain compliance with Nasdaq listing requirements could lead to delisting, severely impairing liquidity and market value.
• The company may be unable to secure sufficient additional capital or generate positive cash flows to satisfy its obligations, potentially forcing it to pursue strategic alternatives such as curtailing operations, selling assets, or bankruptcy.
• The ongoing Civil Investigative Demand from the U.S. Attorneys Office for the Eastern District of Pennsylvania regarding claims submitted to federal insurers for injectable human tissue therapy products introduces legal and financial uncertainty.
• The company's ability to continue as a going concern is dependent on securing additional financing, which is not assured.
• The NexGel transaction, while potentially significant, is subject to milestone payments and royalties, the achievement of which is not guaranteed.
• The company has experienced defaults and ongoing disputes with creditors, including Helena and BioCellgraft, which could lead to further financial strain.
• The effectiveness of internal controls over financial reporting remains a concern, with material weaknesses identified in control environment, risk assessment, control activities, information and communication, and monitoring.

Future Outlook

The company's future outlook is highly uncertain, with substantial doubt cast on its ability to continue as a going concern. Success hinges on securing additional financing, achieving revenue growth to reach break-even operating cash flows, and successfully navigating Nasdaq compliance issues. Strategic alternatives, including severe operational curtailment, asset sales, or bankruptcy, are being considered if capital cannot be secured.

Management Comments

• Management has evaluated the Company's current financial position, liquidity, capital resources, and projected cash flows and has determined that there is substantial doubt about the Company's ability to continue as a going concern.
• The Company has generally not been profitable and since its inception, the Company has incurred significant operating losses and used net cash for operating activities.
• Management is also actively seeking additional capital through public or private equity offerings, debt financings, strategic collaborations, or other financing transactions.
• The Company is taking steps to regain compliance with all applicable Nasdaq rules, but there can be no assurance that it will do so within the applicable periods, and failure to do so could result in the delisting of the Company's common stock.
• In connection with this realignment, we reduced personnel and other expenditures associated with certain commercial and product development functions. These actions are intended to reduce operating costs and concentrate investment on our cellular therapy programs and manufacturing capabilities.

Industry Context

StockSavvy.ai notes that Celularity operates in the highly competitive and capital-intensive regenerative medicine and cellular therapy sector. The company's focus on placenta-derived therapies for age-related diseases places it at the forefront of a growing field, but also requires significant R&D investment and faces long development timelines and regulatory hurdles. The recent strategic shift to focus on core cell therapy and manufacturing, while divesting certain biomaterials assets, reflects a common strategy for companies in this space to streamline operations and conserve capital.

Comparison to Industry Standards

• The company's significant operating losses and accumulated deficit are not uncommon for early-stage biotechnology and regenerative medicine companies investing heavily in R&D and clinical trials. However, the severity of the going concern warning and Nasdaq non-compliance are concerning indicators.
• Competitors in the regenerative medicine space, such as Mesoblast and Athersys, have also faced financial challenges and regulatory hurdles, highlighting the inherent risks in the industry.
• The trend towards strategic partnerships and out-licensing, as seen with the NexGel transaction, is a standard practice in the industry to monetize assets and generate non-dilutive revenue streams.
• The company's focus on allogeneic therapies derived from postpartum placentas positions it within a specific niche, aiming for scalable, off-the-shelf solutions, which is a key differentiator compared to autologous cell therapies.

Management Changes

Corporate Governance

Legal Proceedings

• Civil Investigative Demand from the U.S. Attorneys Office for the Eastern District of Pennsylvania regarding claims submitted to federal insurers for injectable human tissue therapy products.
• Celularity Inc. v. Evolution Biologyx, LLC, et al.: Settlement reached on major issues, agreement being documented.
• TCWGlobal v. Celularity Inc.: Case settled in April 2026 after a default and subsequent agreement to pay $100, then two payments of $125.
• Hackensack Meridian Health v. Celularity Inc.: Company accrued $668 for clinical trial costs after a joint review of invoices; default judgment granted to HUMC.
• Shareholder Derivative Action (Dorrance v. Diamandis): Settled for $3 in cash and $300 worth of restricted stock to plaintiffs counsel.

Related Party Transactions

• CEO promissory note: $4.6 million outstanding as of March 31, 2026, with maturity extended to December 31, 2026.
• CEO's daughter employed as Vice President, Corporate Strategy & Business Development.
• Technology Services Agreement with Fountain Life Management LLC, where the Company's CEO and a Director are founding partners. Revenues from this agreement were $196 for the three months ended March 2026.

Stakeholder Impact

• Shareholders: Potential delisting from Nasdaq, significant dilution from future capital raises, and ongoing uncertainty regarding the company's viability.
• Creditors: Risk of non-payment or delayed payment, as evidenced by defaults and settlement negotiations with Helena and others.
• Employees: Potential for significant operational curtailment or insolvency, impacting job security. Recent leadership changes also indicate restructuring.
• Suppliers: Potential for delayed payments or reduced business due to financial constraints.
• Customers: Uncertainty regarding the long-term availability of products and services, particularly in light of the NexGel transaction and ongoing financial challenges.

Next Steps

• Regain compliance with Nasdaq listing requirements.
• Secure additional financing to fund operations and meet obligations.
• Continue to focus resources on cellular therapy programs and manufacturing capabilities.
• Pursue revenue-generating opportunities through third-party manufacturing services, biobanking, and retained biomaterials activities.
• Resolve ongoing disputes and settlement negotiations with creditors such as Helena and Sequence LifeScience, Inc.
• Implement remediation plans for identified material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

The company is facing severe financial distress, evidenced by a going concern warning, significant operating losses, and Nasdaq non-compliance. While strategic transactions and a recent financing provide some liquidity, the ongoing risks, including potential delisting and the need for substantial future capital, outweigh any short-term positives. The recommendation is to sell due to the high probability of further value erosion and the significant uncertainty surrounding the company's survival.

Keywords

regenerative medicine, cellular therapy, placenta-derived, biobanking, biomaterials, going concern, Nasdaq non-compliance, financial statements